- Company info
- News & events
- Investors
- Contacts & help
News archive for 2006
Find below ReNeuron's archived press releases for 2006
Results of exercise of warrants. 14/12/06
Guildford, UK, 14 December 2006: ReNeuron Group plc (LSE: RENE) today announces that the Company has raised approximately £1.9 million from the …
Read articleReNeuron announces filing IND application to the FDA for ReN001. 06/12/06
ReNeuron files IND application to commence human clinical studies with ReN001 stem cell therapy for stroke First such application to use neural (…
ReNeuron and CellSeed announce collaboration using ReNcellTM liver cell lines. 30/11/06
Guildford, UK, 30 November 2006: ReNeuron Group plc (LSE: RENE.L) and CellSeed Inc., a privately owned tissue engineering company based in Tokyo, …
Interims: Notification of Interim Results. 23/11/06
Guildford, UK, 22 November 2006: ReNeuron Group plc (LSE: RENE.L) today announces that it will report its interim results for the six months ended 30 …
ReNeuron and Millipore announce market launch of ReNcellTMneural stem cell lines. 20/11/06
Guildford,UK, 20 November 2006: ReNeuron Group plc (LSE:RENE.L) and Millipore Corporation (NYSE:MIL), announce the market launch of ReNeuron's …
Notice to Warrant Holders. 15/11/06
Guildford, UK, 15 November 2006: ReNeuron Group plc (LSE: RENE) gives notice reminding Warrant holders that, in accordance with the terms of the …
ReNeuron to present ReN001 Stroke data. 09/10/06
ReNeuron to Present at American Neurological Association Conference Results to Form Part of Data Package to the US FDA In Support of Application to …
Results of 2006 Annual General Meeting. 21/09/06
Guildford, UK, 21 September 2006: ReNeuron Group plc (LSE: RENE) today announces that all resolutions put to its Shareholders at its 2006 Annual …
Warrant Holder Meeting. 21/09/06
Guildford, UK, 21 September 2006: ReNeuron Group plc (LSE: RENE) today announces that all resolutions put to Warrant holders at a meeting of Warrant …
ReNeuron 2006 Annual General Meeting. 23/08/06
Guildford, UK, 23 August 2006: ReNeuron Group plc (LSE: RENE) today announces that it has sent notice to its Shareholders and Warrant holders …
ReNeuron appoints Principal Investigator for Phase l clinical study with its ReN001 stem cell therapy for stroke. 23/08/06
ReNeuron Group plc (LSE: RENE) today announces that it has appointed Professor Douglas Kondziolka MD, MSc, FRCS, FACS as Principal Investigator for …
ReNeuron to present new safety data regarding its stem cell expansion technology and its ReN001 stem cell line for stroke. 29/06/06
Guildford, UK, 29 June 2006: ReNeuron Group plc (LSE: RENE) today announces that it will be presenting significant new data concerning both its c-…
ReNeuron Group plc Preliminary Results for the year ended 31 March 2006. 28/06/06
Operational Highlights Significant progress with late pre-clinical development of lead ReN001 stroke therapy, including repeat efficacy and dose …
ReNeuron Group plc Announcement of Placing. 28/06/06
Guildford, UK: 28 June 2006: ReNeuron Group plc (the "Company") today announces that it has received commitments in respect of a placing of 5,500,000 …
Notification of Preliminary Results. 26/06/06
Guildford, UK, 26 June 2006: ReNeuron Group plc (LSE: RENE.L) today announces that it will report its preliminary results for the year ending 31 March …
ReNeuron to participate in European Stem Cells & Regenerative Medicine Congress 2006. 05/06/06
Guildford, UK, 5 June 2006: ReNeuron Group plc (LSE: RENE.L) today announces that it will participate in the European Stem Cells & Regenerative …
ReNeuron and Chemicon enter into agreement for exclusive sale and marketing of ReNcell neural stem cell lines. 18/04/06
Guildford, UK, 18 April 2006: ReNeuron Group plc (LSE: RENE.L) today announces that it has signed an agreement with Chemicon International, Inc. ('…
ReNeuron enters into cell supply agreement with StemCells, Inc.. 18/04/06
Guildford, UK, 18 April 2006: ReNeuron Group plc (LSE: RENE.L) today announces that it has entered into a further agreement with StemCells, Inc. ('…
ReNeuron announces intention to raise funds through international placing. 05/04/06
Guildford, UK, 5 April 2006: ReNeuron Group plc (AIM: RENE) announces that it proposes to raise up to £8.5 million via a non pre-emptive …
ReNeuron announces initial pre-clinical data with its ReN003 retinal stem cell programme and signs collaboration agreement with Schepens Eye Research Institute. 04/04/06
Guildford, UK, 4 April 2006: ReNeuron Group plc (LSE: RENE.L) today announces initial survival efficacy data with its ReN003 stem cell therapy …
ReNeuron announces successful completion of cell banking with ReN001 stem cell therapy for stroke. 08/03/06
Guildford, UK, 8 March 2006: ReNeuron Group plc (LSE: RENE.L) today announces that it has successfully completed the scale-up and cell banking of its …
ReNeuron to present at 2006 BioSquare conference. 07/03/06
Guildford, UK, 7 March 2006: ReNeuron Group plc (LSE: RENE.L) today announces that it will participate in the 2006 BioSquare conference at the …
ReNeuron announces initial pre-clinical data with its ReN004 human stem cell lines for Parkinson's disease. 16/02/06
Guildford, UK, 16 February 2006: ReNeuron Group plc (LSE: RENE) today announces that initial in vivo testing of its ReN004 candidate stem cell lines …
ReNeuron signs manufacturing contract with Angel Biotechnology for its ReN005 stem cell line for Huntington's disease. 07/02/06
Guildford, UK, 7 February 2006: ReNeuron Group plc (LSE: RENE.L) today announced that it has signed a manufacturing contract with Angel Biotechnology …
ReNeuron announces further positive pre-clinical efficacy data with ReN001 stem cell therapy for stroke. 06/02/06
Guildford, UK, 24 January 2006: ReNeuron Group plc (LSE: RENE.L) today announces that it has generated further positive pre-clinical efficacy data …
ReNeuron receives Notice of Allowance from US Patent Office for neural stem cell transplantation patent application. 24/01/06
ReNeuron Group plc (LSE: RENE.L) today announced that it has received a Notice of Allowance from the US Patent and Trademark Office concerning a key …
Top of page